A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1
Latest Information Update: 04 Aug 2022
At a glance
- Drugs Enzastaurin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms ENGINE
- Sponsors Denovo Biopharma
- 28 Jul 2022 Status changed from active, no longer recruiting to completed.
- 03 Feb 2022 Planned End Date changed from 1 Oct 2022 to 1 Sep 2023.
- 03 Feb 2022 Planned primary completion date changed from 1 Oct 2021 to 1 May 2022.